Velagliflozin

Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used for managing non-insulin-dependent diabetes mellitus in animals. It lowers blood glucose levels by enhancing glucose excretion through urine. Please note that the European Medicines Agency (EMA) has issued a warning regarding the use of Velagliflozin. You can read more about this in the specific SPC. Read more

Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used for managing non-insulin-dependent diabetes mellitus in animals. It lowers blood glucose levels by enhancing glucose excretion through urine. Please note that the European Medicines Agency (EMA) has issued a warning regarding the use of Velagliflozin. You can read more about this in the specific SPC.

Essential insights

• Inhibition of Glucose Reabsorption: Velagliflozin blocks SGLT2 in the proximal tubules of the kidneys, preventing the reabsorption of glucose from the filtrate.
• Improved Glycemic Control: By promoting glucose excretion, blood sugar levels are effectively reduced.
• Protection Against Hyperglycemia: Reduces the risk of diabetes-related complications.
• Selective Toxicity: Velagliflozin is selectively designed to target SGLT2, which is primarily located in the kidneys, minimizing the impact on other organs and systems.